Chapter 67: Substance-Related and Addictive Disorders

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine treating a disease where the patient's own brain is actively lying to them just to keep them sick.

You can't just put a cast on it, you can't surgically remove it, and sometimes your most powerful diagnostic tool isn't a lab test or a scan, it's literally the specific words you choose to use in the exam room.

Yeah, it completely upends how we traditionally think about medicine.

We usually want things to be binary,

broken or not broken, but with this we are operating in a landscape full of gray areas.

Welcome to the Deep Dive.

Today we're sitting down just with you, essentially for a one -on -one clinical strategy session.

Our mission here is to master the assessment and management of substance -related and addictive disorders.

And this is specifically tailored for you, the advanced practice nursing student.

Exactly.

We're going to explore the whole journey of treating these disorders, starting with the foundational science of who is vulnerable, and then moving through how to spot the physiological red flags in your clinic.

And finally, how to build an evidence -based interprofessional management plan.

Right, we aren't just going to hand you a list of facts to memorize.

No, definitely not.

We want to make sure you understand the how and the why behind the clinical guidelines from Chapter 67.

So when you're actually face -to -face with a complex case study or a real patient, you know exactly how to think through it.

Okay, let's unpack this.

Because before you can even begin to assess a patient, you have to understand the sheer scale of this disease.

The numbers are just staggering.

In 2019 alone, an estimated 20 .4 million individuals, that's age 12 and older,

met the criteria for a substance use disorder, or SUD.

That's a massive demographic.

It is.

And within that massive group, there are two incredibly vulnerable populations that you, as a clinician, need to be hyper aware of.

Adolescents and geriatric patients.

Let's look at adolescents first.

I mean, we all know teenagers are risk -takers.

But physiologically, why is this demographic so uniquely vulnerable?

Well, it really comes down to the architecture of neurodevelopment.

The human brain is actually not fully developed until approximately age 25.

And we're talking specifically about the prefrontal cortex here, which is the area that governs impulse control.

Right, the breaks of the brain.

Exactly, the breaks.

But it's more than just poor decision -making.

When an adolescent uses substances, it literally overloads the developing brain with dopamine.

The brain's reward system is just, it's hit with this unnatural massive wave of pleasurable feelings.

And the brain likes homeostasis, right?

It wants balance.

Yeah.

So I'm guessing it tries to defend itself against that massive flood.

Precisely.

To compensate for that overload, the brain down -regulates.

It actually reduces the number of dopamine receptors to try and balance things out.

But doing that damages the neuronal connections.

So once the substance wears off, the adolescent is left with a severely depleted baseline.

Wow.

Yeah.

Their ability to experience normal pleasure from everyday activities is just gone.

And that's the primary mechanism that drives them back to the substance.

They're just trying to feel normal again.

That makes a lot of sense.

Now, on the completely opposite end of the spectrum, you have the geriatric population.

I'd imagine the mechanism of vulnerability there is, well, entirely different.

Oh, completely, Darren.

For older adults, the massive risk is overdose.

And it's largely driven by the physiological changes of aging combined with polypharmacy.

Right, because they're often on so many different medications.

Exactly.

As we age, our liver clearance slows down, our kidney function decreases, and this is a big one, our ratio of body fat to water changes.

This means medications stay in the system much longer and at much higher concentrations.

So if a geriatric patient is managing multiple chronic conditions with multiple prescriptions, say, I don't know, a sedative for sleep and an opioid for arthritis,

they're essentially walking on a tightrope.

They absolutely are.

As an advanced practice nurse, your radar always has to be up for the need to deprescribe.

You have to constantly evaluate if potentially inappropriate medications, especially those sedatives or opioids, can be safely tapered to prevent adverse drug reactions or accidental overdoses.

Which brings us to a really critical point.

And that's the clinical language we use when treating these populations.

We hear a lot about transitioning our terminology, right, saying, person with an SUD instead of addict,

or documenting that a patient is testing positive instead of having dirty urine.

Words matter.

They really do.

But let me ask you about the reality of clinical practice.

Because I understand the theory of person -first language, but when you have a waiting room full of patients and you're running, like,

30 minutes behind, does taking the time to consciously reframe your language from addict to person with an SUD really change the physiological outcome for the patient?

Or is it just us trying to be overly polite?

That is the exact question every student asks.

And the answer is definitively yes, it changes the outcome.

It is not about being polite, it's about clinical efficacy.

Really?

How so?

Well, words like addict or dirty elicit intensely negative associations and punitive attitudes.

And not just from society, but implicitly from healthcare providers.

When a patient feels that stigma, their allostatic load, which is their chronic stress level, it spikes.

They feel judged, they shut down, and ultimately, they avoid care.

So they essentially drop out of the treatment plan entirely.

Exactly.

When you use person -first language, you demonstrate that the person has a medical problem rather than implying they are the problem.

This decreases systemic bias in the clinic and it significantly improves patient retention.

And since SUD is a chronic relapsing disease, keeping your patient engaged in treatment isn't just a nice goal, it is literally a matter of life and death.

Wow.

Okay, so words are actual clinical tools.

Now beyond the clinic, we also have to look at how the broader environment shapes this landscape.

And the COVID -19 pandemic is a prime example of an environmental stressor that just completely fractured the system.

Oh, the pandemic created a perfect storm for SADs.

You had stay -at -home orders, a severe economic recession, sudden job loss, and just extreme isolation.

People were entirely cut off from their support systems.

Their sponsors, their group meetings, their families.

All of it, gone overnight.

And this triggered massive waves of relapses.

By the fifth month of the pandemic, opioid -related deaths had surged and alcohol sales had skyrocketed.

It's tragic.

But in looking at the source material for this chapter,

this crisis also forced a really necessary evolution in how we actually deliver care.

Right.

We had to adapt.

Yes.

The silver lining was the rapid expansion of telemedicine.

Historically, there were huge barriers to getting treatment.

But during the pandemic, Medicare relapsed its coverage rules, which suddenly made care far more accessible, especially for rural populations who couldn't just drive two hours to a clinic.

And it probably removed the stigma of physically walking through the front doors of a rehab facility too.

Exactly.

Furthermore, SAMHS, the Substance Abuse and Mental Health Services Administration, they relaxed their stringent rules, permitting stable patients to receive 28 days of take -home doses for opioid use disorder medications.

It was a massive, necessary shift toward more person -centered, trusting care.

So knowing who is vulnerable and what environment they are navigating leads us to explore how that vulnerability is fundamentally built into the brain's hardware.

Let's get into the path of physiology and the genetics of SUD.

The foundation here rests on what we call Single Nucleotide Polymorphisms, or SNPs.

An SNP is basically a single -letter variation in a person's genetic code.

But it's crucial to understand that there is no single addiction gene.

So you don't just inherit a binary switch that says you will or won't develop an SUD.

Right, exactly.

Instead, these disorders occur when multiple SNPs interact with environmental variables during critical developmental periods.

For example, specific SNPs like ADH1B or SLC39A8 are strongly associated with an increased risk for developing an alcohol use disorder.

I was thinking about this, and Stahl's suspension bridge analogy from the text is absolutely perfect here.

So think of your patient's underlying genetics, like the steel cables and towers of a suspension bridge.

The more of those risky SNPs they have, like that ADH1B variation, the weaker the structural integrity of their bridge.

That's a great visual.

Now, the cars and heavy trucks driving over that bridge,

those represent life stressors.

Childhood trauma, corporate burnout, isolation, or a global pandemic.

That is a phenomenal way to visualize what we call stress diathesis.

The genetic diathesis is the weak bridge.

The environmental stress is the heavy traffic.

If you have a strong bridge, it can handle a lot of heavy trucks without breaking.

But if you have a weak bridge, even moderate traffic can cause a structural collapse.

Let's apply this to a specific clinical scenario to make it real for the students listening.

Consider the case of Karen, a 43 -year -old corporate executive.

She presents to the clinic complaining of increased work -related stress and insomnia.

Right.

And as a clinician, you run your standard screening tools.

Her PHQ -9, which screens for depression, and her iudite, which screens for alcohol use, both come back with elevated scores.

Okay, so the red flags are there.

They are.

And when we look at her whole picture, we discover she has a genomic profile with those exact SNP variations we mentioned, ADH1B and SLC39A8.

So she was fundamentally born with a weaker bridge for alcohol use disorder.

Add in a history of childhood trauma and her current intense corporate stress.

Those are the heavy trucks speeding over her bridge.

So as an APN student listening to this, how do you handle that in the exam room?

Because you can't exactly rewrite Karen's DNA.

Yeah.

And you definitely can't undo her childhood trauma.

And you shouldn't be feralistic about it either.

The key clinical takeaway here is to shift your locus of control.

Don't focus on what you can't change, like the genomic vulnerability or the past.

Focus entirely on what you can control.

Which is the care plan.

Exactly.

You establish a strong non -judgmental therapeutic relationship.

You deliver evidence -based care.

Essentially, you become the support system that helps reinforce and maintain that bridge so it can withstand the traffic.

Okay.

So if we understand the structural vulnerability of the bridge, the next logical question is, how do we spot when it's starting to sway or collapse in the clinic?

Let's talk about clinical presentation and assessment strategies.

The gold standard approach for assessment is the SD or PEP model.

That stands for screening, brief intervention, and referral to treatment.

And this framework relies heavily on motivational interviewing.

So we aren't just lecturing the patient about the dangers of drugs.

Not at all.

It's a non -confrontational, empathetic style of conversation designed to help the patient identify their own internal motivations for change.

You guide them to argue for their own recovery, rather than you arguing against their addiction.

That sounds great in theory, but with so many different substances out there, how do you even prioritize what to look for without getting totally overwhelmed during a 15 -minute assessment?

You focus on the specific, undeniable hallmarks of the most common substances.

Let's break them down, starting with alcohol.

As clinicians, our baseline here is knowing the NIAAA low -risk limits.

For men under 65, it's no more than 14 drinks a day and no more than two a day.

For women and older adults, it's strictly half that.

No more than seven a week and one a day.

Let's pause there, because I think a lot of people just memorize those numbers without understanding why.

Why do women and older adults have exactly half the limit of men?

It's pure physiology.

Women generally have lower levels of gastric alcohol dehydrogenase.

That's the enzyme in the stomach that breaks down alcohol before it even hits the bloodstream.

They also generally have a lower volume of body water compared to fat, meaning the alcohol becomes more highly concentrated in their blood.

And for older adults, as we mentioned earlier, hepatic metabolism slows down.

So a single drink hits these populations much harder and stays around much longer.

And we also need to correlate this with blood alcohol concentration, or BAC levels.

Yes.

At .05, you see mild sedation and relaxation.

But by the time a patient hits .4 or higher, the central nervous system is so depressed, you are looking at coma, respiratory failure, or even death.

What about cannabis?

The clinical presentation there has to be evolving, considering how much the drug itself has changed over the years.

Radically evolving.

THC potency has skyrocketed.

In the 1970s, average potency was around 0 .5%.

Today, it is frequently over 15%, and concentrates can be much, much higher.

Wow, that's a massive jump.

It is.

This means we are seeing significantly higher dependency rates and much more severe withdrawal profiles.

As an APN, you need to understand the timeline here.

The physical withdrawal symptoms, things like irritability and insomnia, they usually peak in the first week.

But because THC is highly lipophilic… Meaning it's stored in the fat cells and leaches out slowly, right?

Exactly.

Because of that, the cannabinoid receptors in the brain need a full four weeks of absolute abstinence to reset and regain regular functioning.

During those four weeks, cognitive impairment and intense cravings will linger.

Good to know.

Now opioids feel like a totally different beast, especially because the withdrawal looks so much like a severe case of the flu.

Muscle aches, tearing eyes, runny nose, usually starting about 24 hours after the last use.

But from what I'm reading, the real danger isn't just surviving the withdrawal itself, it's the relapse risk afterward.

How do we assess that risk up front?

That's where you utilize the Opioid Risk Tool, or ORT.

It's a validated five -question screener you should use before ever prescribing an opioid.

It doesn't just ask about past drug use, it looks at family history of substance abuse and, crucially, history of pre -adolescent sexual abuse.

It acknowledges that trauma and genetics are massive predictors.

Exactly.

They are massive predictors for developing an opioid use disorder.

Next on the list are sedative, hypnotics, and anxiolytics, so your barbiturates and benzodiazepines.

And there is a massive red flag safety warning here for clinical practice that we need to Absolutely.

Listen closely to this withdrawal from barbiturates or benzodiazepines as a life -threatening medical emergency.

You cannot simply tell a patient to taper off these at home on their own.

Why is it so dangerous compared to other withdrawals?

What's happening in the brain?

It's because of how these drugs interact with GABA, which is the primary inhibitory neurotransmitter in the brain.

Essentially, GABA is the brain's brakes.

Benzodiazepines artificially enhance these brakes, so if a patient stops taking them abruptly, the brakes are suddenly completely removed.

Oh, wow.

Yeah.

And glutamate, which is the brain's excitatory neurotransmitter, the gas pedal, it takes over unchecked.

This leads to massive electrical storms in the brain, causing fail, seizures, and delirium.

That's terrifying.

So how do you manage that?

These patients require hospitalization and a medically supervised taper using a specific tool like the CIWA -B scale.

The Clinical Institute Withdrawal Assessment Scale for Benzodiazepines.

Right.

The CIWA -B helps you quantify exactly how severe their tremors, sweating, or anxiety are so you can dose the tapering medications accurately and keep them safe.

I cannot stress this enough.

Do not try to manage severe benzo withdrawal alone in an outpatient primary care setting.

Understood.

Finally, we have stimulants and hallucinogens.

For stimulants like methamphetamine, the mechanism of action causes severe vasoconstriction and cardiac strain.

You have to be prepared for major cardiovascular risks like myocardial infarction or stroke alongside profound psychiatric symptoms.

We're talking violent behavior and persistent psychosis.

And hallucinogens.

For those, you need to be aware of the rising trend of microdosing, which is taking tiny sub -hallucinogenic fractions of LSD or psilocybin.

While some patients self -medicate for mood or creativity, you must assess for unexpected panic reactions or perceptual distortions that could lead to accidental injury.

Okay, so you've gathered all this detailed assessment data.

Now we hit the really challenging part.

Diagnostic reasoning and differential diagnosis.

How does an advanced practice nurse pin down the exact DSM -5TR diagnosis without getting totally fooled by overlapping clinical pictures?

The DSM -5TR anchors these disorders in transdiagnostic phenomena.

Essentially, across almost all substances, you are looking for four core pillars.

Impaired control, like intense cravings.

Physical dependence, which covers tolerance and withdrawal.

Social impairment.

And risky use.

And how do you determine the severity?

The severity of the disorder, whether it's mild, moderate, or severe, is dictated purely by how many of the 11 specific diagnostic criteria the patient meets.

But wait, let me push back on this for a second.

If the physiological withdrawal symptoms for severe alcohol dependence and benzodiazepine dependence both remove those GABA breaks we talked about.

And they look nearly identical.

The tremors, the sweating, the seizures.

How does a student definitively tell them apart in the ER or clinic?

Or what if someone is using synthetic cathinones, like bath salts, which perfectly mimic a primary psychotic disorder?

It's incredibly difficult.

And it's the true art and science of differential diagnosis.

You absolutely cannot rely on the clinical presentation alone.

You must conduct meticulous history taking, gather collateral information from family members or previous providers, and run highly specific lab tests.

Furthermore, you have to be highly vigilant about NPS.

NPS, the new psychoactive substances.

Yes.

The pipeline of designer drugs that are constantly entering the market.

These clandestine labs tweak the molecular structure of the drug just enough to evade standard immunoassay drug screens.

Because the standard test is looking for a specific molecular key to fit its lock.

Exactly.

If the designer drug changes one carbon ring, the test reads negative.

So you have a negative drug screen, but a patient who is actively intoxicated or psychotic.

In those moments, your detailed history taking is literally your only reliable compass.

You also have to carefully map out dual diagnoses.

Which means distinguishing the baseline psychiatric disorder from the temporary substance -induced state.

Yes.

Is the patient profoundly depressed because they have underlying major depressive disorder?

Or are they just experiencing the severe dopamine crash and dysphoria of cocaine withdrawal?

You have to parse that out over time.

Because if you don't treat the underlying psychiatric disorder, they will simply use the substance again to self -medicate.

The two are mutually reinforcing.

And arriving at an accurate diagnosis naturally dictates safe, patient -centered management.

So let's talk about evidence -based management and anti -key medication -assisted treatment.

NEN8 is the absolute cornerstone of treating opioid and alcohol use disorders.

But you have to clearly understand your scope of practice.

For opioid use disorder, a medication like methadone is strictly restricted.

You cannot prescribe it from a standard primary care office.

It has to be administered in a SAMHS -certified opioid treatment program.

But advanced practice nurses have other options now, right?

Yes.

Thanks to the 2016 CRI Act, the Comprehensive Addiction and Recovery Act, APMs, gained the ability to obtain a waiver to prescribe buprenorphine directly from their own offices.

Which is a huge deal, because buprenorphine is a partial agonist.

It covers the opioid receptor just enough to stop the agonizing withdrawal and block cravings, but it doesn't give the full respiratory depression or the high of heroin.

But before you even write that buprenorphine prescription, you and the patient have a lot of groundwork to cover.

The medication initiation checklist in the text is quite extensive.

It has to be.

You must comprehensively check their labs.

Why do we check liver function tests?

Because medications like buprenorphine are metabolized in the liver, and we need to ensure their liver can handle it.

Makes sense.

And why do we screen for HIV, hepatitis B, hepatitis C, and syphilis?

Because of the high risk associated with intravenous drug use and high risk sexual behaviors,

you need to ensure their vaccinations are up to date.

You must have a frank, documented discussion about safe medication storage at home to prevent pediatric exposure.

And the urine testing.

Yes.

You need to set clear, compassionate expectations for regular urine drug testing.

But frame it as a measure of safety, not punishment.

Let's ground this complex management in a real -world application.

The SAMHSA case study in Chapter 67 is a perfect example.

It outlines a 30 -year -old Hispanic mother.

She has a history of severe trauma, has engaged in sex work, and actively uses heroin, cocaine, and alcohol.

She recently lost custody of her children, has just tested positive for HIV, and is profoundly depressed and expressing suicidal ideation.

It's a heavy, highly complex presentation.

It really is.

So as an APN, looking at this mountain of clinical and social issues,

where do you even begin?

You begin by ruthlessly triaging.

You cannot fix everything in one visit.

You have to divide your interventions into immediate, life -saving priorities.

Your short -term goals versus chronic, stabilizing management, which are your long -term goals.

Okay, walk us through the short -term triage for her.

Short -term goal number one is preserving her life.

That means addressing the imminent danger of suicide.

You immediately involve a psychiatric mental health provider for a safety assessment.

Goal two is getting her out of immediate physical danger by utilizing social workers to find emergency shelter housing.

Goal three is providing immediate, compassionate HIV education and counseling about transmission.

And goal four is addressing her escalating chaotic cocaine and heroin use by initiating emirate for the opioids and utilizing motivational groups for the stimulants.

And then once she's physically safe and stabilized, you shift to the long -term goal.

Exactly.

Long -term, you are looking at managing her underlying depression with ongoing cognitive behavioral therapy and potentially SSRI medication.

You are working continuously with social services and the legal system to help her meet the requirements to regain custody of her children, which requires stable housing and demonstrated sobriety.

And critically, you are establishing a strict, ongoing antiretroviral treatment plan to manage her HIV.

So what does this all mean?

If we step back and look at it, it means your management plan is never, ever a solo act.

It is deeply, fundamentally interprofessional.

You are relying on social workers, psychiatrists, housing staff, infectious disease specialists.

Absolutely.

Safe management doesn't magically end the moment the prescription is sent to the pharmacy, which brings us to the final ongoing phase of care.

Follow -up, referral, and health promotion.

Because the reality is, patients form incredibly strong, complicated attachments to their substance use lifestyle.

They do.

We often forget that recovery involves a grieving process.

It's not just the chemical dopamine hit they are giving up.

It's their entire community.

It's the people they socialize with, their primary coping mechanisms for stress, their daily routine.

That's their whole world.

Exactly.

The terrifying prospect of losing those relationships and facing the world without that armor often drives rationalization and relapse.

It sounds like treating a substance use disorder effectively means you aren't just treating the patient.

You are treating the patient's entire environment.

You hit the nail on the head.

You have to educate the patient's support system.

Often, well -meaning family members don't realize they are actually enabling the destructive behavior or operating out of deep codependency.

You need to actively recommend support groups not just for the patient, like AA or NA, but specifically for the family, like Al -Anon, to help them establish healthy boundaries.

And in all of this, we can't forget about the core principle of harm reduction.

Never.

Health promotion in SUD recognizes that relapse is often part of the disease process.

Our primary job is keeping the patient alive long enough for recovery to take hold.

That means proactively prescribing meloxone to patients and training their families on how to use it to reverse fatal opioid overdoses.

It means putting aside your judgment and teaching them the importance of utilizing sterilized injection equipment to prevent the spread of endocarditis, HIV, and hepatitis C.

We've covered a massive amount of clinical ground today.

We've gone from the genomic architecture of the brain and those vulnerable SNPs all the way through the specific physiological mechanisms of withdrawal and finally to the exact steps of an interprofessional evidence -based management plan.

You now have a comprehensive framework to approach this field.

It's not just about passing a test, it's a holistic clinical strategy to save lives.

Which leaves us with a final thought for you to mull over.

Throughout our discussion, we've seen that substance use disorders are profoundly influenced by neurobiology.

Your genetics literally dictate the structural strength of your suspension bridge.

Yet when we look at the most critical, life -saving interventions for a patient like the mother in our case study, securing stable housing, mitigating past trauma, building social support, and addressing systemic bias with our language, it raises a really provocative question.

It does.

Is the advanced practice nurse's most powerful tool actually their prescription pad?

Or is it their ability to screen for and heal systemic social stress?

It's the constant tension between biology and the environment.

And navigating that tension is what makes this specialty so incredibly challenging and so deeply vital to our communities.

Think about that as you continue to build your clinical practice.

Thank you from the Last Minute Lecture Team.

Keep studying, keep asking questions, and we'll see you next time on the Deep Dive.